Development and external validation of a nomogram to predict lymph node invasion after robot assisted radical prostatectomy.


Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
02 2020
Historique:
received: 11 06 2018
revised: 30 07 2019
accepted: 02 10 2019
pubmed: 16 11 2019
medline: 15 4 2021
entrez: 16 11 2019
Statut: ppublish

Résumé

Prediction of lymph node invasion (LNI) after radical prostatectomy has been rarely assessed in robotically assisted laparoscopic radical prostatectomy (RALP) series. We aimed to develop and externally validate a pretreatment nomogram for the prediction of LNI following RALP in patients with high- and intermediate-risk prostate cancer. 1654 RALP patients were prospectively collected between 2009 and 2016 from academic and community hospitals. We included patients with intermediate- and high-risk prostate cancer who underwent pelvic lymph node dissection (e-PLND). Logistic regression analysis was applied to construct a nomogram to predict LNI. Centers were randomly assigned to the training cohort (80%) and validation cohort (20%). The discriminative accuracies were evaluated by the areas under the curve and by the calibration plot. The net benefit of the nomogram to predict LNI was assessed by decision curve analysis and a cut-off was proposed. In total, 14% of the patients in our cohort had pN1 disease. Applying logistic regression analysis, the following covariates were chosen to develop the nomogram: initial PSA, clinical T stage, biopsy Gleason sum, and proportion of positive biopsy cores. The nomogram showed a median discriminative accuracy of 73% and excellent calibration. The net benefit of the model ranged between 7% and 51% predicted risk of LNI. A cut-off to perform e-PLND was set at 7%. This would permit a 29% of avoidable e-PLND, missing 9.4% of patients with LNI. We developed and externally validated a nomogram to predict LNI in patients treated with RALP from a prospective, multi-institutional, nationwide series. A risk of LNI > 7% is proposed as cut-off above which e-PLND is recommended.

Sections du résumé

BACKGROUND
Prediction of lymph node invasion (LNI) after radical prostatectomy has been rarely assessed in robotically assisted laparoscopic radical prostatectomy (RALP) series. We aimed to develop and externally validate a pretreatment nomogram for the prediction of LNI following RALP in patients with high- and intermediate-risk prostate cancer.
METHODS
1654 RALP patients were prospectively collected between 2009 and 2016 from academic and community hospitals. We included patients with intermediate- and high-risk prostate cancer who underwent pelvic lymph node dissection (e-PLND). Logistic regression analysis was applied to construct a nomogram to predict LNI. Centers were randomly assigned to the training cohort (80%) and validation cohort (20%). The discriminative accuracies were evaluated by the areas under the curve and by the calibration plot. The net benefit of the nomogram to predict LNI was assessed by decision curve analysis and a cut-off was proposed.
RESULTS
In total, 14% of the patients in our cohort had pN1 disease. Applying logistic regression analysis, the following covariates were chosen to develop the nomogram: initial PSA, clinical T stage, biopsy Gleason sum, and proportion of positive biopsy cores. The nomogram showed a median discriminative accuracy of 73% and excellent calibration. The net benefit of the model ranged between 7% and 51% predicted risk of LNI. A cut-off to perform e-PLND was set at 7%. This would permit a 29% of avoidable e-PLND, missing 9.4% of patients with LNI.
CONCLUSIONS
We developed and externally validated a nomogram to predict LNI in patients treated with RALP from a prospective, multi-institutional, nationwide series. A risk of LNI > 7% is proposed as cut-off above which e-PLND is recommended.

Identifiants

pubmed: 31727561
pii: S1078-1439(19)30399-0
doi: 10.1016/j.urolonc.2019.10.001
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

37.e11-37.e20

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Lorenzo Tosco (L)

Urology, University Hospitals Leuven, Leuven, Belgium; Humanitas University, Department of Biomedical Sciences, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele - Milan, Italy. Electronic address: gaetan.devos@uzleuven.be.

Gaëtan Devos (G)

Urology, University Hospitals Leuven, Leuven, Belgium.

Greet De Coster (G)

Belgian Cancer Registry, Brussels, Belgium.

Thierry Roumeguère (T)

Department of Urology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.

Wouter Everaerts (W)

Urology, University Hospitals Leuven, Leuven, Belgium.

Thierry Quackels (T)

Department of Urology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.

Peter Dekuyper (P)

Department of Urology, AZ Maria Middelares, Gent, Belgium.

Ben Van Cleynenbreugel (B)

Urology, University Hospitals Leuven, Leuven, Belgium.

Nancy Van Damme (N)

Belgian Cancer Registry, Brussels, Belgium.

Elisabeth Van Eycken (E)

Belgian Cancer Registry, Brussels, Belgium.

Filip Ameye (F)

Department of Urology, AZ Maria Middelares, Gent, Belgium.

Steven Joniau (S)

Urology, University Hospitals Leuven, Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH